ANT-GROUP
Marriott International has signed a partnership agreement with Ant Group to enhance its digital operations in the Chinese market by providing Alipay members with various benefits when they sign up for the Marriott Bonvoy Rewards Program, Marriott’s signature loyalty program. Marriott International will deliver more membership benefits with upgrades on products and services to further improve the consumer experience under its strong brand portfolio.
The partnership with Alipay, the leading digital open platform under Ant Group, will further expand the potential for Marriott International to serve more customers in China. This is in addition to the more than 10 million newly-enrolled members the company has gained through various channels since 2017, including its official flagship storefront in partnership with Fliggy, as well as various consumer partnerships with Alibaba Group and Ant Group. The partnership also presents more opportunities for the tourism industry to embrace digital transformation in its operations.
“Marriott International has a long history in China, and with more than 450 operating hotels across 23 brands in Greater China, we are committed to catering to the needs and preferences of all our guests,” said Mr. Henry Lee, President, Greater China, Marriott International. “Our diverse brand portfolio offers further opportunities for innovative collaborations with Ant Group. To support the recovery of the travel industry, we are looking to offer exclusive travel experiences for high-net-worth members using Alipay.”
“We are delighted to extend our partnership with Marriott International, to enhance its digital operations and provide Alipay users with improved benefits,” said Kelly Li, General Manager overseeing user operations at Alipay and Vice President of Ant Group. “Marriott International operates with a strong brand portfolio and connects us with a diverse range of clients with its award-winning Marriott Bonvoy Rewards Program. Following this partnership, we look forward to working with more partners and providing more comprehensive and exclusive experiences to Alipay users.”
“We studied what Chinese consumers want, and partnered with Ant Group to provide a new way of enjoying our Marriott Bonvoy loyalty program,” said Ms. Julie Purser, Vice President, Marketing, Loyalty & Partnerships, Asia Pacific, Marriott International. “With this development, we hope to keep up with digital marketing trends in China. We are excited to offer travelers more ways to follow their passion and experience unforgettable journeys.”
From May 24, 2022 to March 31, 2023, qualified Alipay members can sign up for a Marriott Bonvoy membership through the app and enjoy different levels of benefits. They can collect a special digital coupon (worth 30 RMB) for afternoon tea at Marriott International hotels and join a lucky draw to enjoy afternoon tea by spending 1 RMB at Marriott International.
From May 24, 2022 to June 24, 2022, new members can enjoy breakfast by spending only 1 RMB at selected Marriott International hotels in various cities, including Guangzhou, Shenzhen, Hangzhou, Chengdu and Sanya. Through Marriott International’s company-wide ‘Commitment to Clean’ policy, the company is committed to meeting local hygiene and safety guidelines to ensure the health and safety of all guests.
Looking ahead, Marriott International will continue to deepen its partnership with Alibaba Group and Ant Group to bring more inspirations for travelers with exclusive membership benefits.
About Marriott International
Marriott International, Inc. (NASDAQ: MAR) is based in Bethesda, Maryland, USA, and encompasses a portfolio of more than 8,000 properties under 30 leading brands spanning 139 countries and territories. Marriott operates and franchises hotels and licenses vacation ownership resorts all around the world. The company offers Marriott Bonvoy®, its highly-awarded travel program. For more information, please visit our website at www.marriott.com , and for the latest company news, visit www.marriottnewscenter.com . In addition, connect with us on Facebook and @MarriottIntl on Twitter and Instagram .
About Ant Group
Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable. For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220529005094/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom